SCHEMBL15046526

SCHEMBL15046526

c1ccc(CN2CCCNCCCNCCC2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 12/20 0.75
SIGMAR1 Q99720 3/20 0.75
MEN1 O00255 2/20 0.73
KMT2A Q03164 2/20 0.73
HRH3 Q9Y5N1 2/20 0.73
CHRM2 P08172 1/20 0.73
CHRM1 P11229 1/20 0.73
ADRA2C P18825 1/20 0.73
CCR2 P41597 1/20 0.73
CXCL12 P48061 1/20 0.73
BLM P54132 1/20 0.73
TDP1 Q9NUW8 1/20 0.73
TSHR P16473 2/20 0.62
ALDH1A1 P00352 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
HIF1A Q16665 1/20 0.62
CYP2D6 P10635 2/20 0.59
MC4R P32245 1/20 0.53
CYP3A4 P08684 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3779720 0.98 CXCR4 (0.78) CXCR4SIGMAR1MEN1KMT2AHRH3
SCHEMBL3994310 0.95 CXCR4 (0.83) CXCR4SIGMAR1MEN1KMT2AHRH3
SCHEMBL255099 0.94 SIGMAR1 (0.85) CXCR4SIGMAR1MEN1KMT2AHRH3
SCHEMBL10316935 0.94 SIGMAR1 (0.85) CXCR4SIGMAR1MEN1KMT2AHRH3
SCHEMBL3999326 0.94 CXCR4 (0.79) CXCR4SIGMAR1MEN1KMT2AHRH3
SCHEMBL30641657 0.93 CXCR4 (0.81) CXCR4SIGMAR1MEN1KMT2AHRH3
SCHEMBL31616422 0.93 SIGMAR1 (0.82) CXCR4SIGMAR1MEN1KMT2AHRH3
Hydrochloric Acid SCHEMBL7422770 0.93 SIGMAR1 (0.82) CXCR4SIGMAR1MEN1KMT2AHRH3
SCHEMBL9168824 0.93 CXCR4 (0.76) CXCR4SIGMAR1MEN1KMT2AHRH3
Pyrrolidine SCHEMBL15516038 0.91 SIGMAR1 (0.72) CXCR4SIGMAR1MEN1KMT2AHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233971-B2 Lipomacrocycles and uses thereof AGAVE PHARMA, INCORPORATED 2016-01-12 US disclosed
US-20130156851-A1 LIPOMACROCYCLES AND USES THEREOF AGAVE PHARMA, INCORPORATED 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130156851-A1 LIPOMACROCYCLES AND USES THEREOF LIPC, LIPA, LIPE CXCR4 373/4885SIGMAR1 3061/4885MEN1 1689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.